Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

F2G gets $70 million to develop the antifungal olorofim

by Gina Vitale
August 14, 2022 | A version of this story appeared in Volume 100, Issue 28

 

The structure of olorofim.

F2G, an antifungal developer, has received $70 million from investors to ­advance its antifungal therapy olorofim in the US. Olorofim is used to treat invasive aspergillosis and other rare mold infections. It’s part of the first new class of antifungals in 2 decades, F2G says. In May, the ­Japanese firm Shionogi paid $100 million to the company in exchange for rights to develop and commercialize olorofim in Europe and Asia.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.